优化HLA脱敏:血清稀释策略和针对移植中抗体介导排斥风险的平台特定MFI值
Dominique Bertrand1, Céline Dard2, Rangolie Kaveri3
1Department of Nephrology, Kidney Transplantation and Hemodialysis, Rouen University Hospital, Rouen, France.
Frontiers in immunology
|October 20, 2025
概括
血清稀释增强了移植候选人的捐赠者特异性抗体 (DSA) 评估,改善了对抗体中介排斥 (ABMR) 风险预测. 这有助于高度敏感的患者的器官接受策略.
科学领域:
- 移植免疫学 移植免疫学
- 临床诊断 临床诊断 临床诊断
背景情况:
- 高敏感性移植 (KT) 候选人面临抗体中介排斥 (ABMR) 风险增加,特别是在脱敏感化期间.
- 通过Luminex单抗原珠 (SAB) 试验,精确的捐赠者特异性抗体 (DSA) 量化是至关重要的,但面临信号和和平台可变性等挑战.
研究的目的:
- 评估血清稀释对DSA量化和ABMR风险预测对无敏化KT接受者的影响.
- 为了比较Immucor-Werfen (IM) 和One Lambda-Thermofisher (OL) SAB平台之间的DSA评估.
主要方法:
- 一个双中心研究分析了20个敏感的KT接受者进行脱敏的抗HLA抗体配置文件.
- 血清样本在IM和OLSAB平台上在脱敏化前后进行未稀释和1:10稀释的测试.
主要成果:
- 稀释的脱敏前血清与脱敏后的DSA水平相关性更好 (IM的R2>0.90,OL的R2>0.85).
- 在预测早期ABMR时,DSA的总和 (sDSA) 优于免疫主导的DSA (iDSA).
- 接收器操作特征 (ROC) 分析显示了良好的预测能力 (AUC 0.79-0.88),IM提供了优越的IDSA歧视. 为ABMR风险分层提出了IM特定的MFI值.
结论:
- 血清稀释完善了对无敏化KT候选者的DSA强度解释和风险评估.
- 整合特定平台的MFI截止值和基于稀释的分析,可以增强高度敏感患者的器官接受策略.
关键词:
哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈脱敏感化 脱敏感化稀释剂的稀释方法是高度敏感的高度敏感的腎臟移植 腎臟移植卢米内克斯 (Luminex) 公司更多相关视频
相关概念视频
Kidney Transplant I: Introduction
339
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
339
Kidney Transplant II: Surgical Procedure
303
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
303
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
207
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
207


